Piper Sandler analyst Matt O’Brien raised the firm’s price target on Teleflex to $280 from $225 and keeps a Neutral rating on the shares. The firm anticipates some concern around the political backdrop here in the U.S., but doubts med tech will be pressured regardless of who wins the Presidency. However, volumes and pricing for 2024 should be good across the sector. Piper sees little GLP related risk for the full year and anticipates 2024 will be a good year for med tech stocks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TFX:
- Teleflex price target raised to $272 from $228 at RBC Capital
- Teleflex now offers its Titan SGS™ Stapler with Staple Line Reinforcement
- Teleflex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Teleflex price target raised to $270 from $221 at Truist
- Teleflex price target raised to $265 from $225 at Wells Fargo
